AU Patent

AU2018346602B2 — Compounds, compositions and methods for increasing CFTR activity

Assigned to Kineta Inc · Expires 2024-10-17 · 2y expired

What this patent protects

The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein.

USPTO Abstract

The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018346602B2
Jurisdiction
AU
Classification
—
Expires
2024-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Kineta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.